How repurposing a drug in a COVID-19 trial could benefit people with cancer

3 March 2021, by Catherine Pickworth

People with cancer have been severely affected by COVID-19, with the pandemic impacting how they're diagnosed, treated and cared for.

When the pandemic began, scientists across the UK looked at what they could do to support the COVID-19 efforts—from volunteering in a testing facility to 3-D printing masks.

And with an excellent track record in setting up early stage (phase 1) cancer trials quickly, our Centre for Drug Development were determined to help. Not only did they manage to keep their cancer trials going during the pandemic, but at no extra cost to the charity, they also lent their expertise to fight the COVID-19 pandemic.

In May 2020, Latus Therapeutics approached us, having secured funding worth up to £1m from the medical research charity LifeArc, to set up and run the SPIKE–1 trial. We spoke with Professor Kev Dhaliwal from the University of Edinburgh, chief investigator of the SPIKE–1 trial, which is testing if a drug called camostat can help stop people with COVID-19 developing severe disease and prevent them from deteriorating and being hospitalized.

Repurposing drugs

Dhaliwal, who specializes in respiratory and translational medicine, had been urgently considering potential avenues for COVID-19 treatment.

"There was evidence from scientists in Germany around repurposing a drug, used to treat inflammation of the pancreas, that might also be able to reduce the severity of COVID-19 by blocking an enzyme the virus needs to get into cells. The key aim is to treat as early as possible"

The team immediately started to look at setting up their own studies that could help those who were particularly at high risk of COVID-19 complications, including certain cancer patients whose immune systems may be compromised while undergoing treatment.

The lockdown trial

"Our first hurdle was getting access to potential drugs. We were introduced to Dr. Bobojon Nazarov, founder of the biotech company Latus Therapeutics, which established the framework for the SPIKE-1 trial, and who knew Cancer Research UK might be able to help through their Centre for Drug Development."

With the backing of LifeArc, Cancer Research UK's drug development expertise and the generosity of Ono Pharmaceutical who supplied the drug free of charge, the team were able to get the trial off the ground.

Dhaliwal says that one of the great things about the study and drug, camostat, is that it can be taken at home as a tablet, which is helpful during a pandemic. They began what Dhaliwal describes as a 'hospital-at-home-trial' – where people take a diary, measure their oxygen levels using a finger clip, their temperature by an ear thermometer and
have daily talks with our nursing team. "We hoped
the drug would be able to reduce the severity of
their symptoms, with the end goal being to prevent
them having to go to hospital, and also provide
some much needed support at home."

A second hurdle

But once they’d managed to design the trial, and
get the team in place, Dhaliwal explains that they
came across a second roadblock—letting people
know it’s happening.

"It's currently open in Edinburgh, Cardiff, Preston
and Rhyl, but it's been hard to let people know this
is an option." The trial has now been given Urgent
Public Health (UPH) status, which means that it’s a
national priority trial and will get extra support to
accelerate recruitment of patients.

"Now that we’ve got UPH status, we hope this will
speed things up, allow us to open the trial to more
sites and work out if this drug is as effective as we
hope it could be."

What does this mean for people with cancer?

Dhaliwal says this couldn’t be more timely, as he’s
seen an increase in people presenting with later
stage lung cancer in hospital. "I think that's due to
several factors; from people not wanting to go to
their GP during the pandemic, to delays to some
services. It's never been more vital for us to get
back on track."

Recent figures suggest that around 40,000 fewer
people started cancer treatment across the UK last
year and many people are waiting for diagnostic
tests, so it’s crucial that cancer services recover as
quickly as possible to help get through the backlog.

"To do that, we need to reduce the strain on the
healthcare services from COVID-19 patients, by
reducing hospital admissions and severity of the
disease, which we think camostat could help to do."

"The other challenge for cancer patients is that
many of them have weakened immune systems,
which makes them more vulnerable to severe
COVID-19 disease. We're hoping that, if camostat
is proven to be effective, it could benefit people who
are living with cancer right now by stopping the
virus entering their cells."

Still relevant

Dhaliwal stresses that this is part of a multi-faceted
approach to tackling COVID-19, and vital to get the
country back to normal.

"First is something everyone can do: staying home
and staying safe. Second is the vaccination
program, and we would encourage everyone who is
eligible to be vaccinated. But the vaccine won’t be
the answer for everyone—we will also need
treatments that reduce the need for hospitalization
and prevent death from COVID-19—the third arm of
the approach."

Dhaliwal says this is especially relevant to cancer
patients who, during this pandemic, have seen first-
hand the knock on effect that COVID-19 has had
on cancer services within the NHS.

"This drug could offer a real opportunity to minimize
the disruption of the pandemic going forward as it
could help prevent people with COVID-19 being
hospitalized and alleviate pressures on the NHS
and help get cancer services back on track."

Looking to the future, the team are excited to
increase recruitment. "Our first milestone will be
when we managed to recruit and analyze using
camostat in 100 patients, to make sure it’s safe and
effective before looking to roll camostat out more
broadly in larger trials and then hopefully into the
NHS more broadly."

More information: More information about the
SPIKE-1 trial: www.cancerresearchuk.org/fundi ...
opment-spike-1-trial

Provided by Cancer Research UK